Navigation Links
Pharmacyclics Announces It Received Nasdaq Notification
Date:4/21/2008

SUNNYVALE, Calif., April 21 /PRNewswire-FirstCall/-- Pharmacyclics, Inc. (Nasdaq: PCYC) today announced that it received a Nasdaq staff deficiency letter on April 17, 2008 indicating that, for the last 30 consecutive days, the bid price for Pharmacyclics' common stock has closed below the minimum bid price of requirement of $1.00 per share for continued inclusion on The Nasdaq Global Market under Marketplace Rule 4450(a)(5). In accordance with Marketplace Rule 4450(e)(2), Pharmacyclics has 180 calendar days, or until October 14, 2008, to regain compliance. If Pharmacyclics does not regain compliance by October 14, 2008, Nasdaq will provide written notification that Pharmacyclics' common stock will be delisted, after which Pharmacyclics may appeal the staff determination to the Nasdaq Listing Qualifications Panel if it so chooses. There can be no assurance that Pharmacyclics will satisfy Nasdaq's conditions for continued listing, that any potential appeal or hearing for a stay of delisting will be successful or that Pharmacyclics' common stock will remain listed on The Nasdaq Global Market.

About Pharmacyclics

Pharmacyclics is a pharmaceutical company developing innovative products to treat cancer and immune mediated diseases. The company is leveraging its small-molecule drug development expertise to build a pipeline in oncology and other diseases based on a wide range of targets, pathways and mechanisms. More information about the company, its technology, and products can be found at http://www.pharmacyclics.com. Pharmacyclics(R), and the "pentadentate" logo(R) are registered trademarks of Pharmacyclics, Inc.


'/>"/>
SOURCE Pharmacyclics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Pharmacyclics Announces Multiple Presentations at the American Association for Cancer Research Annual Meeting
2. Boston Scientific Announces Results for First Quarter Ended March 31, 2008
3. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2008 Financial Results
4. Monogram Biosciences Announces First Quarter 2008 Financial Results Conference Call
5. Ocular Biopharmaceutical Company Charlesson Announces $1.6MM in New Funding and Upcoming Presentations at The Association for Research in Vision and Ophthalmology
6. CardioVascular BioTherapeutics, Inc. Announces Update on Timing of Form 10-K Filing
7. Susan G. Komen for the Cure(R) Announces Largest Grants Slate Ever: $100 Million to Speed Delivery of Breast Cancer Discoveries, Cures
8. Cell Therapeutics, Inc. Announces Receipt of Letter From the NASDAQ Stock Market Regarding Non-Compliance With the Minimum Bid Price Requirement
9. US Oncology Announces Resignation of Chief Financial Officer
10. Biotherm Announces a Unique Dermobiotic Three-Step Anti-Cellulite Slimming Treatment
11. Osteotech Announces First Quarter Earnings Release and Conference Call Schedule
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2016)... ... November 30, 2016 , ... SSCI, the established leader in small-molecule cocrystal technology ... latest FDA guidance on pharmaceutical cocrystals as drug substance . The Lunch ... , The event follows the successful November 15th event that took place in Burlingame, ...
(Date:11/30/2016)... (PRWEB) , ... November 30, 2016 , ... ... in the development of a new orally administered treatment for Alzheimer’s disease (AD), ... results of a Phase 2a clinical trial of T3D-959 in mild to moderate ...
(Date:11/30/2016)... London, UK (PRWEB) , ... November 30, 2016 , ... ... old offices on Haymarket after five years and look forward to continuing their expansion ... heart of Soho, an area which has been traditionally favoured by the creative industries, ...
(Date:11/30/2016)... ... November 30, 2016 , ... Microbial ... venture founded by Arianna Huffington, as part of the Thrive Global pop-up store. ... Kit, enabling purchasers to explore the microorganisms in their gut, collectively known as ...
Breaking Biology Technology:
(Date:11/29/2016)... , Nov. 29, 2016 BioDirection, a ... point-of-care products for the objective detection of concussion and ... company has successfully completed a meeting with the U.S. ... Tbit™ blood test Pre-Submission Package. During the meeting company ... system as a precursor to commencement of a planned ...
(Date:11/24/2016)... Nov. 23, 2016 Cercacor today introduced Ember ... their trainers non-invasively measure hemoglobin, Oxygen Content, ... and Respiration Rate in approximately 30 seconds. Smaller than ... and immediate access to key data about their bodies ... training regimen. Hemoglobin carries oxygen to ...
(Date:11/19/2016)... , Nov. 18, 2016 Securus Technologies, a ... for public safety, investigation, corrections and monitoring, announced today ... competitor, ICSolutions, to have an independent technology judge determine ... most modern high tech/sophisticated telephone calling platform, and the ... that they do most of what we do – ...
Breaking Biology News(10 mins):